Aliases & Classifications for Reading Disorder

MalaCards integrated aliases for Reading Disorder:

Name: Reading Disorder 12 15
Specific Reading Disorder 71 32
Developmental Reading Disorder 71
Dyslexia 71
Reading 17

Classifications:



External Ids:

Disease Ontology 12 DOID:13365
ICD9CM 34 315.09
ICD10 32 F81.0
UMLS 71 C0037789 C0154631 C0476254 more

Summaries for Reading Disorder

Disease Ontology : 12 A learning disability involing difficulty reading resulting primarily from neurological factors which affect any part of the reading process.

MalaCards based summary : Reading Disorder, also known as specific reading disorder, is related to dyslexia 2 and periventricular nodular heterotopia, and has symptoms including aprosodia An important gene associated with Reading Disorder is DCDC2 (Doublecortin Domain Containing 2). The drugs Betamethasone and Dipivefrin have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and breast.

Related Diseases for Reading Disorder

Diseases related to Reading Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1067)
# Related Disease Score Top Affiliating Genes
1 dyslexia 2 33.8 KIAA0319 DCDC2
2 periventricular nodular heterotopia 32.3 ROBO1 KIAA0319L KIAA0319 DNAAF4 DCDC2 CMIP
3 stuttering 30.8 FOXP2 CNTNAP2 ASPRV1
4 attention deficit-hyperactivity disorder 30.3 KIAA0319 GRIN2B FOXP2 DCDC2 CNTNAP2
5 developmental coordination disorder 30.2 IQCB1 CEBPD ATP2C2 ASPRV1
6 dyslexia 30.1 TDP2 ROBO1 MRPL19 KIAA0319L KIAA0319 IQCB1
7 writing disorder 30.0 IQCB1 DNAAF4 DCDC2
8 articulation disorder 30.0 FOXP2 CNTNAP2 CEBPD ASPRV1
9 speech disorder 30.0 KIAA0319 GRIN2B FOXP2 CNTNAP2 CEBPD ASPRV1
10 dyscalculia 29.9 KIAA0319 IQCB1 DNAAF4 DCDC2 CFAP47 ASPRV1
11 echolalia 29.7 FOXP2 CNTNAP2 CEBPD
12 childhood apraxia of speech 29.7 FOXP2 CNTNAP2
13 autism spectrum disorder 29.6 GRIN2B FOXP2 DNAAF4 DIP2A CNTNAP2 CMIP
14 autism 29.4 GRIN2B FOXP2 DOCK4 DNAAF4 CNTNAP2 CELF4
15 learning disability 29.3 ROBO1 KIAA0319L KIAA0319 IQCB1 GCFC2 FOXP2
16 benign epilepsy with centrotemporal spikes 29.2 KIAA0319 IQCB1 GCFC2 FOXP2 DNAAF4 CNTNAP2
17 pervasive developmental disorder 29.2 IQCB1 GRIN2B FOXP2 CNTNAP2 CELF4 CEBPD
18 specific language impairment 29.1 ROBO1 MRPL19 KIAA0319 IQCB1 GCFC2 FOXP2
19 specific developmental disorder 28.9 KIAA0319 IQCB1 GRIN2B FOXP2 DNAAF4 DCDC2
20 speech and communication disorders 28.5 ROBO1 KIAA0319 IQCB1 GRIN2B GCFC2 FOXP2
21 hyperlexia 12.1
22 dyslexia 1 12.1
23 hypertension, essential 11.7
24 macular degeneration, age-related, 1 11.6
25 presbyopia 11.6
26 farsightedness 11.4
27 motion sickness 11.4
28 myopia 11.4
29 alzheimer disease 11.3
30 cataract 11.3
31 alexia 11.3
32 retinitis pigmentosa 11.3
33 developmental dyspraxia 11.3
34 retinal disease 11.3
35 stargardt macular degeneration 11.3
36 retinal detachment 11.3
37 flna-related periventricular nodular heterotopia 11.3
38 macular telangiectasia type 2 11.3
39 cone-rod dystrophy 2 11.3
40 digeorge syndrome 11.3
41 adrenoleukodystrophy 11.3
42 leber optic atrophy 11.3
43 alpha-thalassemia 11.3
44 west syndrome 11.3
45 auditory agnosia 11.3
46 color blindness 11.3
47 macular dystrophy, retinal, 1, north carolina type 11.1
48 retinoschisis 1, x-linked, juvenile 11.1
49 vitelliform macular dystrophy 11.1
50 verbal auditory agnosia 11.1

Graphical network of the top 20 diseases related to Reading Disorder:



Diseases related to Reading Disorder

Symptoms & Phenotypes for Reading Disorder

UMLS symptoms related to Reading Disorder:


aprosodia

Drugs & Therapeutics for Reading Disorder

Drugs for Reading Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 757)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
2
Dipivefrin Approved Phase 4 52365-63-6 3105
3
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
4
Budesonide Approved Phase 4 51333-22-3 63006 5281004
5
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
6
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
7
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
8
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
9
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
10
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
11
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
12
Polyestradiol phosphate Approved Phase 4 28014-46-2
13
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
14
Racepinephrine Approved Phase 4 329-65-7 838
15
Carbon monoxide Approved, Investigational Phase 4 630-08-0 281
16
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
17
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
18
Remifentanil Approved Phase 4 132875-61-7 60815
19
Silver sulfadiazine Approved, Vet_approved Phase 4 22199-08-2 441244
20
Sulfadiazine Approved, Investigational, Vet_approved Phase 4 68-35-9 5215
21 Pinaverium Approved Phase 4 59995-65-2
22
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
23
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
24
Glimepiride Approved Phase 4 93479-97-1 3476
25
Nitric Oxide Approved Phase 4 10102-43-9 145068
26
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
27
Liraglutide Approved Phase 4 204656-20-2 44147092
28
Pimozide Approved Phase 4 2062-78-4 16362
29
Clozapine Approved Phase 4 5786-21-0 2818
30
Warfarin Approved Phase 4 81-81-2 6691 54678486
31
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
32
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 444025 9865442
33
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
34
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
35
Adalimumab Approved Phase 4 331731-18-1 16219006
36
Verapamil Approved Phase 4 52-53-9 2520
37
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
38
Pasireotide Approved Phase 4 396091-73-9 9941444
39
Apixaban Approved Phase 4 503612-47-3 10182969
40
Etanercept Approved, Investigational Phase 4 185243-69-0
41
Aminocaproic acid Approved, Investigational Phase 4 60-32-2 564
42
Lumefantrine Approved Phase 4 82186-77-4 6437380
43
Artemether Approved Phase 4 71963-77-4 119380 68911
44
Amodiaquine Approved, Investigational Phase 4 86-42-0 2165
45
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
46
Artesunate Approved, Investigational Phase 4 88495-63-0 6917864 5464098
47
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
48
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
49
Tibolone Approved, Investigational Phase 4 5630-53-5
50
Drospirenone Approved Phase 4 67392-87-4 68873

Interventional clinical trials:

(show top 50) (show all 2219)
# Name Status NCT ID Phase Drugs
1 Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Dyslexia) Unknown status NCT00111371 Phase 4 Levodopa
2 Tear Osmolarity Over Time With Artificial Tears Unknown status NCT01227226 Phase 4 Artificial tears
3 An Open Single Centre Evaluation of the Reactivity of the T.R.U.E. Test Quaternium-15 Patch and a Real Use Exposure in Subjects Known to Be Allergic to Quaternium-15 Unknown status NCT00311454 Phase 4 T.R.U.E.Test
4 Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients With Headache and Dizziness or Epilepsy and Clinical Indication for an Angiography by Magnetic Imaging Unknown status NCT00132223 Phase 4 Contrast agent
5 Comparison of Adverse Drug Reactions Associated for Oxycodone and Morphine in Postoperative Pain After Abdominal Hysterectomy Unknown status NCT02936934 Phase 4 Morphine;Oxycodone
6 Description of the Ability to Learn How to Handle Inhaler Devices in COPD Unknown status NCT02813200 Phase 4 Seretide® Diskus® 500/550 μg;Ultibro® Breezhaler® 110/50 μg;Spiriva® Respimat® 2,5 μg
7 Does a Low Exhaled Nitric Oxide Level Exclude a Clinical Benefit From Inhaled Corticosteroids in Suspected Asthma: A Randomised, Placebo Controlled Trial Unknown status NCT02771717 Phase 4 Budesonide (Pulmicort);Placebo - dummy inhaler
8 Ketamine Reduces Tourniquet Pain In Patients Undergoing Lower Limb Surgery Under Spinal Anaesthesia Unknown status NCT03357055 Phase 4 Ketamine;Normal saline
9 The Effect of Treatment for ED on Quality of Life and Satisfaction in a Group of Patients Without Prior Complaints of Sexual Dysfunction Unknown status NCT00313898 Phase 4 sildenafil (viagra)
10 A Randomized Controlled Study of Nifecardia SRFC (Nifedipine) and Adalat OROS (Nifedipine) in the Treatment of Patients With Essential Hypertension Unknown status NCT00173667 Phase 4 Nifedipine 30 mg GITS
11 Non-surgical Treatment of Carpal Tunnel Syndrome: Night Splint Versus Local Corticosteroid Infiltration: Clinical Randomized Trial Unknown status NCT03196817 Phase 4 betamethasone dipropionate, betamethasone disodium phosphate and lidocaine 2%
12 Effect of Vitamin d Supplementation on the Control of Persistent Asthma in Children at Dr George Mukhari Academic Hospital, Pretoria, South Africa Unknown status NCT02053402 Phase 4 Vitamin D
13 Treatment for Alcohol Dependence With Gabapentin: A Double Blind Placebo Controlled Randomized Clinical Trial Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
14 This is a 2 Year Follow up Clinical and Radiographic Analysis of a Novel All Polyethelene Glenoid Component in Standard Total Shoulder Arthroplasty. Unknown status NCT01313741 Phase 4
15 Assessment of the Effects of the Combination of Spironolactone to Conventional Pharmacotherapy in Dialysis Patients Unknown status NCT01128101 Phase 4 Spironolactone
16 A Double Blind Randomized Placebo Controlled Study, for Smoking Cessation in Preadmission Clinic. the Use of a Teachable Moment Unknown status NCT00937508 Phase 4 varenicline;placebo
17 MRI With a Lymph Node Specific Contrast Agent: an Alternative for CT-Scanning and Lymph Node Dissection in Patients With Prostate Cancer? Unknown status NCT00185029 Phase 4
18 A Randomized, Double-Blind, Crossover Comparison of Atomoxetine and Placebo in Child Outpatients With Attention-Deficit/Hyperactivity Disorder, Reading Disorder, or Comorbid Attention-Deficit/Hyperactivity Disorder and Reading Disorder. Completed NCT00191906 Phase 4 Atomoxetine Hydrochloride;placebo
19 Neurophysiology of Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Dyslexia: Functional Magnetic Resonance Imaging (fMRI) Measures of Brain Activation During Attention and Reading Tasks Pre- and Post-Atomoxetine Treatment Completed NCT00716274 Phase 4 Atomoxetine;Placebo
20 A Double-Blind Placebo Controlled Study of Atomoxetine Hydrochloride for the Treatment of ADHD in Children and Adolescents With ADHD and Comorbid Dyslexia Completed NCT00607919 Phase 4 Atomoxetine;Placebo
21 Reading ICARD: Interventions for Children With Attention and Reading Disorders Completed NCT01133847 Phase 4 Methylphenidate;Mixed Salt Amphetamine;Atomoxetine;Guanfacine
22 Open-Label Treatment With Atomoxetine Hydrochloride in Child and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Dyslexia Completed NCT00191048 Phase 4 Atomoxetine
23 Project Magnify - A Comparison of Two Strategies (Large Print Versus Optical Aids) for Helping Visually Impaired Students Improve Reading Abilities Completed NCT00366392 Phase 4
24 Impact of the Absence of Steroids on the Evolution of Renal Function and on the Progression of Graft Fibrosis, Quantified by Numerical Method, in Patients With Renal Transplant Completed NCT01541176 Phase 4 Corticotherapy post-transplantation
25 Evaluation of ReAding Speed, Contrast Sensitivity, and Work Productivity in Working Individuals With Diabetic Macular Edema Following Treatment With Intravitreal Ranibizumab Completed NCT02107131 Phase 4 Intravitreal ranibizumab 0.3mg
26 Omega 3/6 Fatty Acids for Reading in Children: A Randomised, Double-blind, Placebo-controlled Trial in 9-year-old Mainstream Schoolchildren in Sweden Completed NCT02557477 Phase 4
27 The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading Completed NCT00733356 Phase 4 Vyvanse
28 Does the Administration of Preop Midazolam Assist in Maintaining Blood Glucose Norms in Non-diabetic Patient During the Perioperative Period Completed NCT01641653 Phase 4 Midazolam
29 Central Venous Catheter-Related Infection: A Prospective Randomized Double-Blind Study Completed NCT00533988 Phase 4
30 Screening for Sleep-disordered Breathing in Routine Cardiology Practice: Validation of the Apnea + Hypopnea Detection by an Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization Therapy-defibrillator (CRT-D) With Impedance-based Respiration Sensor (ApneaScanTM) Completed NCT02045173 Phase 4
31 VITAL - Individualising Therapy for Neovascular AMD With Aflibercept Completed NCT02441816 Phase 4 Aflibercept
32 Clinical Trial of Pinverin (Pinaverium Bromide) to Reduce Bowel Uptake of FDG in a Variety of Cancer Patients Who Undergo FDG PET/CT Completed NCT02173964 Phase 4 pinaverium bromide;water
33 A Random Controlled Trial a Comprehensive Migraine Intervention at the Time of Discharge From the Emergency Department After Treatment for Acute Migraine Completed NCT01071317 Phase 4 Naproxen;Sumatriptan
34 Effects of Dapagliflozin Compared With Glimepiride on Body Composition in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Completed NCT02564926 Phase 4 Dapagliflozin;Glimepiride
35 COST-EFFECTIVENESS STUDY OF THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER IN BRAZIL Completed NCT01228604 Phase 4 methylphenidate (Ritalin®)
36 Language-based Learning Skills and ADHD: Impact of Treatment With Sustained-release Guanfacine Completed NCT01146002 Phase 4 Guanfacine (sustained release)
37 Computerized Cognitive Skills Training in Severe Mental Illness Completed NCT01036282 Phase 4
38 A Pilot Study to Evaluate the Applicability of the Crohn's Disease Endoscopy Index of Severity to Data Obtained by the Colonic Capsule Endoscopy in Ileocolonic Crohn's Disease Completed NCT01183845 Phase 4
39 A Phase IV, Prospective, Open-label, Uncontrolled, European Study in Patients With Neovascular Age-related Macular Degeneration (nAMD), Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to Ranibizumab 0.5mg. Completed NCT02161575 Phase 4 Ranibizumab
40 Prevention Services in Schools for Early Drug Abuse Risk Completed NCT00257088 Phase 4
41 Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Academic, Behavioral and Cognitive Effects of CONCERTA on Older Children With ADHD (The ABC Study) Completed NCT00799487 Phase 4 CONCERTA (methylphenidate HCl) or placebo;CONCERTA (methylphenidate HCl) or placebo
42 The ABC Study: A Double-Blind, Randomized, Placebo-Controlled, Crossover Study Evaluating the Academic, Behavioral, and Cognitive Effects of CONCERTA on Older Children With ADHD Completed NCT00799409 Phase 4 Placebo/ CONCERTA (methylphenidate HCl);CONCERTA (methylphenidate HCl) / Placebo
43 Pimozide Augmentation of Clozapine in Schizophrenia Completed NCT00158223 Phase 4 Pimozide;Placebo
44 A Double-blind Placebo Controlled Trial of Pregnenolone for Depression in Patients With Bipolar Disorders or Recurrent Major Depressive Disorder and a History of Substance Abuse Completed NCT00223197 Phase 4 Pregnenolone
45 The Effects of Long-acting Methylphenidate on Academic Activity and Related Constructs in Children With ADHD: A Randomised Placebo Controlled Trial Completed NCT02501798 Phase 4 Methylphenidate;Placebo
46 Prospective, Non-randomized Multi-center, Controlled Physician-initiated Trial: Rotarex Belgium In-stent Occlusion Completed NCT02212626 Phase 4
47 Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab Completed NCT01717859 Phase 4 Tocilizumab
48 Media Use in Preschooler Study (MUPS) An Office Based Intervention to Improve Media Use in Preschool Children: a Randomized Controlled Trial Completed NCT00959309 Phase 4
49 Estimation of Interleukin-21 Levels in Gingival Crevicular Fluid in Patients With Periodontal Health and Disease Following Non-surgical Periodontal Therapy: A Clinico-biochemical Study Completed NCT02861937 Phase 4
50 Comparison of the Ultra-low-dose Veo Algorithm With the Gold Standard Filtered Back Projection for Detecting Pulmonary Asbestos-related Conditions Completed NCT01955018 Phase 4

Search NIH Clinical Center for Reading Disorder

Genetic Tests for Reading Disorder

Anatomical Context for Reading Disorder

MalaCards organs/tissues related to Reading Disorder:

40
Brain, Testes, Breast, Eye, Heart, Lung, Prostate

Publications for Reading Disorder

Articles related to Reading Disorder:

(show top 50) (show all 237)
# Title Authors PMID Year
1
Effect of READ1 on latent profiles of reading disorder and comorbid attention and language impairment subtypes. 61
31411106 2020
2
Handwriting Delay in Dyslexia: Children at the End of Primary School Still Make Numerous Short Pauses When Producing Letters. 61
32036738 2020
3
Functional connectivity of the reading network is associated with prenatal polybrominated diphenyl ether concentrations in a community sample of 5 year-old children: A preliminary study. 61
31743804 2020
4
Spatial Network Connectivity and Spatial Reasoning Ability in Children with Nonverbal Learning Disability. 61
31953441 2020
5
Assessment for familial pattern and association of polymorphisms in KIAA0319 gene with specific reading disorder in children from North India visiting a tertiary care centre: A case-control study. 61
31814229 2019
6
Pure Alexia: A Combined First-Person Account and Neuropsychological Investigation. 61
31800487 2019
7
Phonological memory problems are magnified in children from language minority homes when predicting reading disability. 61
31685053 2019
8
Cognitive and Behavioural Weaknesses in Children with Reading Disorder and AD(H)D. 61
31645633 2019
9
How Does iReadMore Therapy Change the Reading Network of Patients with Central Alexia? 61
31085605 2019
10
Understanding comorbidity of learning disorders: task-dependent estimates of prevalence. 61
30144072 2019
11
Neural correlates of cognitive control deficits in children with reading disorder. 61
30919230 2019
12
Steady-State Pattern Electroretinogram and Frequency Doubling Technology in Adult Dyslexic Readers. 61
31849443 2019
13
Impact of Somatosensory Input Deficiency on Subjective Visual Vertical Perception in Children With Reading Disorders. 61
31632338 2019
14
Double Trouble: Visual and Phonological Impairments in English Dyslexic Readers. 61
31920790 2019
15
What causes dyslexia? Identifying the causes and effective compensatory therapy. 61
31796709 2019
16
Beyond genes: A systematic review of environmental risk factors in specific reading disorder. 61
29566979 2018
17
Interventions for children with dyslexia: A review on current intervention methods. 61
30350811 2018
18
Amygdala sub-regional functional connectivity predicts anxiety in children with reading disorder. 61
29143475 2018
19
Co-morbidities in Chinese children with attention deficit/hyperactivity disorder and reading disabilities. 61
29271537 2018
20
Randomized trial of iReadMore word reading training and brain stimulation in central alexia. 61
29912350 2018
21
Atypical predictive processing during visual statistical learning in children with developmental dyslexia: an event-related potential study. 61
29907920 2018
22
Sluggish dorsally-driven inhibition of return during orthographic processing in adults with dyslexia. 61
29453081 2018
23
Familial study of attentional and behavioural problems in children with Dyslexia and their first-degree relatives in Indian setting. 61
29500977 2018
24
Does the late positive component reflect successful reading acquisition? A longitudinal ERP study. 61
29159040 2018
25
Dyslexic Characteristics of Chinese-Speaking Semantic Variant of Primary Progressive Aphasia. 61
29061089 2018
26
Recognizing Psychiatric Comorbidity With Reading Disorders. 61
29636707 2018
27
Combined Modality Intervention for ADHD With Comorbid Reading Disorders: A Proof of Concept Study. 61
27895238 2018
28
Unfolding the genetic pathways of dyslexia in Asian population: A review. 61
28619243 2017
29
Altered Structural Connectivity of the Left Visual Thalamus in Developmental Dyslexia. 61
29153326 2017
30
Neurobiological Bases of Reading Disorder Part II: The Importance of Developmental Considerations in Typical and Atypical Reading. 61
29276529 2017
31
Attitudes and knowledge of parents of preschool children about specific learning disabilities. 61
28953831 2017
32
Neural Noise Hypothesis of Developmental Dyslexia. 61
28400089 2017
33
Acquired spatial dyslexia. 61
26272419 2017
34
Comorbidity of Arithmetic and Reading Disorder. 61
26772796 2017
35
Neurobiological bases of reading disorder Part I: Etiological investigations. 61
28785303 2017
36
Dyslexia risk gene relates to representation of sound in the auditory brainstem. 61
28182973 2017
37
Genes, Gender, Environment, and Novel Functions of Estrogen Receptor Beta in the Susceptibility to Neurodevelopmental Disorders. 61
28241485 2017
38
Oculomotor rehabilitation in children with dyslexia. 61
29951425 2017
39
Possible roles for fronto-striatal circuits in reading disorder. 61
27826071 2017
40
Study of the effect of Memantine therapy on the treatment of dyslexia in children. 61
29387124 2017
41
Copy-number variations are enriched for neurodevelopmental genes in children with developmental coordination disorder. 61
27489308 2016
42
Reading disorders and dyslexia. 61
27496059 2016
43
Descriptive epidemiology of prenatal and perinatal risk factors in a Chinese population with reading disorder. 61
27819320 2016
44
Efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in patients with common comorbidities in children, adolescents and adults: a review. 61
27721971 2016
45
Individual Differences in Adult Reading Are Associated with Left Temporo-parietal to Dorsal Striatal Functional Connectivity. 61
26400921 2016
46
Brain mechanisms of recovery from pure alexia: A single case study with multiple longitudinal scans. 61
27422538 2016
47
Translating dyslexia across species. 61
27013331 2016
48
The role of parieto-temporal connectivity in pure neglect dyslexia. 61
27450929 2016
49
[Attention and reading performance in children with ADHD, reading disorder and the combined condition]. 61
27356676 2016
50
Lessons to be learned: how a comprehensive neurobiological framework of atypical reading development can inform educational practice. 61
27766284 2016

Variations for Reading Disorder

Expression for Reading Disorder

Search GEO for disease gene expression data for Reading Disorder.

Pathways for Reading Disorder

GO Terms for Reading Disorder

Biological processes related to Reading Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuron migration GO:0001764 9.13 KIAA0319 DNAAF4 DCDC2
2 vocal learning GO:0042297 8.62 FOXP2 CNTNAP2

Molecular functions related to Reading Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.55 TDP2 ROBO1 MRPL19 KIAA0319L KIAA0319 IQCB1

Sources for Reading Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....